Vyndaqel FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved May 3, 2019)
Brand name: Vyndaqel
Generic name: tafamidis meglumine
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Cardiomyopathy of Transthyretin-Mediated Amyloidosis
Vyndaqel (tafamidis meglumine) is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis.
Development Timeline for Vyndaqel
|May 6, 2019||Approval FDA Approves New Treatments Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) for Heart Disease Caused by Transthyretin Mediated Amyloidosis|
|Jan 14, 2019||US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy|
|Sep 18, 2018||New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting|
|Mar 29, 2018|| Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy|
|Jun 6, 2017||Pfizer Receives FDA Fast Track Designation for Tafamidis for Transthyretin Cardiomyopathy|
|Aug 8, 2016||Pfizer Announces Publication of New Analysis Showing Long-Term Therapy with Vyndaqel (tafamidis) Slowed Progression of Rare Neurodegenerative Disease|
|Jun 18, 2012||FDA Issues Complete Response Letter For Pfizer's Tafamidis Meglumine New Drug Application|
|May 25, 2012||FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer's Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)|
|Feb 15, 2012||FDA Accepts Pfizer's New Drug Application for Tafamidis Meglumine, a Novel, Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)|
|Apr 4, 2011||Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.